Study: Companies regularly don’t tell investors why FDA rejected their drugs
A study in the British Medical looked at company press releases found that they frequently held back information about why the FDA rejected a drug.
Rookie of the Year: Forbes says Keytruda & Opdivo are 2014’s most important new drugs
What was the best new drug of 2014? Forbes‘ Matthew Herper chose two. Herper laid out a solid case for why two new – and highly similar – cancer drugs are standouts this year: Keytruda from Merck and Opdivo from Bristol-Myers Squibb. He writes: These two medicines represent a breakthrough in oncology: unlocking the immune system as a […]
presented by
Rethinking The Entry Point to Healthcare in America: Collaboration in Communities
Healthcare in the U.S. today exists in a complex, fragmented and costly system, and the people this system is designed for deserve a holistic approach to best address their individual health needs.